Article · 13 Feb 2026
Conference abstractPublished 25 Sep 2017
Roadmap to pharmaceutical regulatory harmonization in Pakistan
Indus Pharma (Pvt.) Ltd., Pakistan
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Provision of affordable quality pharmaceuticals is an integral part of every national health policy. Attaining optimal quality standards for pharmaceutical products is impossible without an effective pharmaceutical regulation regime that protects public health by ensuring safe, effective and quality pharmaceuticals and detecting illegal manufacturing and trade. Pakistan, despite having a large Pharmaceutical sector (over 600 manufacturing units; market size of around 3 billion dollars) has not realized its true potential in the area due to non-adherence to globally accepted quality standards. There is a huge unexploited potential for export of the country's pharmaceutical products especially in the context of the GSP Plus status granted to Pakistan by the European Union. History & Challenges: In Pakistan, the ministry of health (MoH) used to regulate drug manufacturing and pricing at the federal level. After the decentralization of the Health Ministry (2011), Drug Regulatory Authority of Pakistan (DRAP) came into being (December 2012). DRAP has been continuously evolving and advancing in its vision and procedures; there is still a long way to go in order to overcome its current challenges like premarket evaluation and registration, post-market surveillance, cost recovery, price control, international harmonization, access to regulated markets and capturing the scientific advancements for modernization of act and regulations etc. Recommendations: Promote harmonization of regulatory processes by adopting globally harmonized standards; establish targeted capacity-building for quality APIs; introduce an online submission system for dossiers/query responses etc., train the regulators; hire more staff and set transparent pricing rules. Conclusion & Significance: Pharma regulatory authorities all over the world are rapidly advancing. Likewise, DRAP is already on its way for reformation and improvement. The recommendations in this presentation may prove helpful for DRAP in its journey towards excellence.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Muhammad Naeem”

